Adenocarcinoma of the prostate is the most common malignancy diagnosed among men in the United States today. Brachytherapy permits conformal radiotherapy and dose escalation, and it offers the convenience of a single-day outpatient procedure which is very attractive to patients with a busy life-style. The reported potency preservation rates with brachytherapy are superior to both external beam radiation therapy (EBRT) and surgery. The older retropubic techniques have been replaced by ultrasound or CT-guided transperineal techniques. Prostate brachytherapy may be temporary or permanent, and the planning techniques for either approach are similar. This review briefly discusses the advantages and limitations of each. Temporary techniques may be used with low dose rate or high dose rate applications. The basic steps include assessing prostate volume by any diagnostic modality (CT or ultrasonography), determining total activity needed to encompass the gland and deliver the appropriate minimum peripheral dose, and determining the pattern of placement of the seeds within the gland. Preplanning may be done either by ultrasound or by CT. The operative technique requires the visualization of the prostate in three dimensions and is performed using combination of ultrasound and fluoroscopy or fluoroscopy in two axes. The New York Hospital technique employs CT-based preplanning along with ultrasound and fluoroscopy during the operative procedure. Special circumstances that necessitate neoadjuvant hormonal therapy include interference from the pubic arch and large volume glands. An analysis of patients with stage T2a disease treated at the New York Hospital-Queens, from 1990-1995, reveals an actuarial clinical freedom from relapse of 79% at 5 years and a 5-year biochemical freedom from relapse of 64% which is comparable to that reported for similar risk groups of disease by other centers. Potency is preserved in greater than 80% of patients in our series. Patient selection criteria include the pre-treatment prostate-specific antigen (PSA) level, tumor grade (Gleason), stage of disease, and presence or absence of bilateral positive biopsies and/or perineural invasion. Based on our review of the literature and our clinical results, we have divided patients with prostate cancer into good, intermediate and poor risk groups. We recommend brachytherapy as the sole procedure for good risk patients, and a combination of external beam radiation therapy (EBRT) and brachytherapy for the intermediate risk group. Future avenues for research include a search for improved imaging techniques and possibly newer isotopes.